Orthofix Medical Inc. - OFIX STOCK NEWS

Orthofix Medical (NASDAQ: OFIX) will release its second quarter 2024 financial results on August 6, 2024, before the market opens. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results.

Participants in the U.S. can join the call by dialing (888) 330-2508, and international participants can dial (240) 789-2735, using the passcode 9556380. A replay will be available for three weeks at (800) 770-2030 in the U.S. and (647) 362-9199 internationally, with the same passcode.

Investors can access the webcast and press release at ir.Orthofix.com. Orthofix regularly updates important information on its Investor Relations page.

Orthofix Medical (NASDAQ: OFIX) has announced the appointment of Michael Finegan as the new Chair of its Board of Directors. Finegan, who has a history with Orthofix, including serving as Chief Strategy Officer for seven years, is currently the CEO of Acera Surgical. Finegan expressed confidence in Orthofix's potential for profitable growth and sustainable shareholder value. The outgoing Chair, Cathy Burzik, was thanked for her leadership. Orthofix's President and CEO, Massimo Calafiore, highlighted Finegan's industry experience as beneficial for the company's next phase of growth.

Orthofix Medical (NASDAQ:OFIX) has named Aviva McPherron as President of Global Operations and Quality. McPherron, previously at Globus Medical and NuVasive, brings extensive experience in clinical services, strategic growth, and operational transformation. She will lead Orthofix's strategy for operations, manufacturing, regulatory, clinical, and quality teams. McPherron's appointment follows the merger of Orthofix and SeaSpine, positioning the company for enhanced growth and operational efficiency. Her compensation includes performance-based and time-based stock units, and options to purchase shares, contingent on meeting specified performance and service criteria.

Orthofix, a global leader in spine and orthopedics, has appointed Julie Dewey as Chief Investor Relations and Communications Officer. Max Reinhardt has also started his role as President of Orthofix's global spine business. Both will join the Executive Leadership Team. Dewey brings extensive experience from her previous roles at Treace Medical Concepts and Wright Medical Group. Orthofix CEO Massimo Calafiore highlights her expertise in market knowledge and growth strategies, which are expected to enhance investor relations and drive profitability. Dewey expresses her excitement to contribute to Orthofix's growth trajectory.

Orthofix Medical has appointed Max Reinhardt as President of its Global Spine business, effective June 10, 2024. Reinhardt, with over 30 years of experience in MedTech and pharmaceuticals, will be a part of the Executive Leadership Team, leading SeaSpine. He has held significant positions at Johnson & Johnson, including Worldwide President of DePuy Synthes Spine, where he achieved the number two market share position in the spine market. Orthofix CEO Massimo Calafiore praised Reinhardt's robust leadership and strategy execution skills. Reinhardt's prior roles also include senior positions at Steris, Olympus, and Pacira Biosciences.

Orthofix, a global leader in spine and orthopedics, has won the 'Best Patient Experience Solution' award at the 2024 MedTech Breakthrough Awards for its STIM onTrack™ mobile app. The app, compatible with FDA-approved bone growth therapy devices like CervicalStim™, SpinalStim™, and PhysioStim™, tracks patient compliance data and aids in recovery by providing daily treatment reminders, usage calendars, and patient-reported outcome measures. The app enhances patient engagement by allowing remote monitoring and direct communication with physicians. This is Orthofix's second consecutive win at the MedTech Breakthrough Awards.

Orthofix Medical Inc. (NASDAQ:OFIX) has received FDA 510(k) clearance to market its innovative Rodeo Telescopic Nail designed to treat deformities or fractures in patients with osteogenesis imperfecta. The device stabilizes limbs and accommodates natural growth in pediatric patients, addressing biomechanical challenges in a streamlined procedure. The system enhances bone fixation in fragile OI patients, optimizes operational efficiency, reduces costs, and lessens contamination risks. This marks Orthofix's dedication to serving the pediatric market with tailored solutions for conditions like OI.

Orthofix Medical Inc. (NASDAQ:OFIX) reported strong first quarter 2024 results with net sales of $188.6 million, a 7.7% increase on a reported basis. The company saw growth across key segments, including Bone Growth Therapies, U.S. Spine Fixation, and Global Orthopedics. Despite a net loss of $36 million, the Non-GAAP Adjusted EBITDA increased to $7.7 million, showing a 220 basis point expansion. Orthofix raised its full-year net sales guidance to $790.0-$795.0 million, emphasizing continued growth and profitability.

Orthofix Medical Inc. (NASDAQ:OFIX) has scheduled the release of its first quarter 2024 financial results on May 7, 2024, before market open. The company will host a conference call and webcast to review the results at 8:30 a.m. ET on the same day. Interested parties can access the conference call by dialing (888) 330-2508 in the U.S. and (240) 789-2735 in other locations, using event passcode 9556380. A replay will be available for three weeks. A webcast and release copy can be found at ir.Orthofix.com.